Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Bahar R, Wong KA, Liu CH, Bowlus CL.

Gastroenterol Hepatol (N Y). 2018 Mar;14(3):154-163.

2.

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R.

N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519.

PMID:
29874528
3.

[Primary biliary cholangitis-established and novel therapies].

Vetter M, Kremer AE.

Internist (Berl). 2018 Jun;59(6):544-550. doi: 10.1007/s00108-018-0427-0. Review. German.

PMID:
29691599
4.

Editorial: Itching to Know: Role of Fibrates in PBC.

Levy C, Lindor KD.

Am J Gastroenterol. 2018 Jan;113(1):56-57. doi: 10.1038/ajg.2017.432.

PMID:
29311728
5.

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.

Bolier R, de Vries ES, Parés A, Helder J, Kemper EM, Zwinderman K, Elferink RPO, Beuers U; Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group.

Trials. 2017 May 23;18(1):230. doi: 10.1186/s13063-017-1966-8.

6.

Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.

Suraweera D, Rahal H, Jimenez M, Viramontes M, Choi G, Saab S.

Liver Int. 2017 Dec;37(12):1877-1886. doi: 10.1111/liv.13477. Epub 2017 Jun 14. Review.

PMID:
28517369
7.

Recent advances in the diagnosis and treatment of primary biliary cholangitis.

Huang YQ.

World J Hepatol. 2016 Nov 28;8(33):1419-1441. Review.

8.

Identification of microRNA profiles associated with refractory primary biliary cirrhosis.

Sakamoto T, Morishita A, Nomura T, Tani J, Miyoshi H, Yoneyama H, Iwama H, Himoto T, Masaki T.

Mol Med Rep. 2016 Oct;14(4):3350-6. doi: 10.3892/mmr.2016.5606. Epub 2016 Aug 9.

PMID:
27511723
9.

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum].

Yin Q, Li J, Xia Y, Zhang R.

Drug Des Devel Ther. 2015 Nov 6;9:5947. doi: 10.2147/DDDT.S98298. eCollection 2015. No abstract available.

10.

Novel Therapies on Primary Biliary Cirrhosis.

Czul F, Levy C.

Clin Liver Dis. 2016 Feb;20(1):113-30. doi: 10.1016/j.cld.2015.08.006. Review.

PMID:
26593294
11.

Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.

Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, Feld JJ.

Aliment Pharmacol Ther. 2016 Jan;43(2):283-93. doi: 10.1111/apt.13465. Epub 2015 Nov 12.

12.

It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology.

Shimoda S, Tanaka A.

Hepatol Res. 2016 Mar;46(5):407-15. doi: 10.1111/hepr.12615. Epub 2016 Jan 30. Review.

PMID:
26518139
13.

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.

Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C.

Drug Des Devel Ther. 2015 Sep 30;9:5407-19. doi: 10.2147/DDDT.S92041. eCollection 2015. Review. Erratum in: Drug Des Devel Ther. 2015;9:5947.

14.

Response to Licinio et al.

Sato K, Hosonuma K, Kusano M, Yamada M.

Am J Gastroenterol. 2015 Jul;110(7):1086-7. doi: 10.1038/ajg.2015.166. No abstract available.

PMID:
26148264
15.

Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases?

Licinio R, Facciorusso A, Castellaneta NM, Di Leo A.

Am J Gastroenterol. 2015 Jul;110(7):1086. doi: 10.1038/ajg.2015.163. No abstract available.

PMID:
26148263
16.

Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis.

Zhu GQ, Huang S, Huang GQ, Wang LR, Lin YQ, Wu YM, Shi KQ, Wang JT, Zhou ZR, Braddock M, Chen YP, Zhou MT, Zheng MH.

Oncotarget. 2015 Sep 15;6(27):24533-49. Review.

17.

Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

Purohit T, Cappell MS.

World J Hepatol. 2015 May 8;7(7):926-41. doi: 10.4254/wjh.v7.i7.926. Review.

18.

Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis.

Zhu GQ, Shi KQ, Huang S, Huang GQ, Lin YQ, Zhou ZR, Braddock M, Chen YP, Zheng MH.

Medicine (Baltimore). 2015 Mar;94(11):e609. doi: 10.1097/MD.0000000000000609. Review.

19.

A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.

Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, Kakizaki S, Kusano M, Yamada M.

Am J Gastroenterol. 2015 Mar;110(3):423-31. doi: 10.1038/ajg.2015.20. Epub 2015 Mar 3.

PMID:
25732417
20.

Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.

Tanaka A, Hirohara J, Nakanuma Y, Tsubouchi H, Takikawa H.

J Gastroenterol. 2015 Jun;50(6):675-82. doi: 10.1007/s00535-014-0998-z. Epub 2014 Sep 20.

PMID:
25239675

Supplemental Content

Loading ...
Support Center